Koji Pharmaceutical -B fell 5.67%, and Hang Seng Medical ETF (513060) turned over 200 million

In the morning, Hang Seng Medical ETF (513060) shocked, fell 2.64%, the turnover exceeded 200 million, and the transaction was active. The premium in the plate is frequent, and the recent net inflows have continued to inflow. Among the ingredients stocks, Koji Pharmaceutical-B, Medicine Health, Chinese Biopharmaceuticals, Cornerstone Pharmaceutical-B, Yao Ming Junuo led.

Zhejiang Business Securities believes that Koji Pharmaceutical-B has continued to increase in research and development in financial aspects and cash flow. R & D investment continues to increase, and 2022 will maintain simultaneously. 2022H1 R & D expenditure of 316 million yuan. We expect to continue to advance with 2022H2 physical tumor CAR-T domestic and North American phase II clinical trials, and R & D expenditure is expected to further increase. Its cash is still abundant, supporting the development of the R & D pipeline.

CT053 is about to be commercialized and has a security advantage. CT053 clinical data is comparable to competing efficacy and better safety. We are optimistic about CT053 to enter the commercialization after entering commercialization. CT041 will become the world's first and only CAR-T to enter the confirmed phase II physical tumor, and it is the first to break through gastric cancer. It shows the treatment effect that is better than existing therapy than existing therapy in patients with GC/GEJ. From the preliminary clinical data of China, the ORR reached 57.1%-61.1%, and MPFS reached 5.6 months, showing a strong advantage in curative effect.

- END -